CTOs on the Move

Cosette Pharmaceuticals

www.cosettepharma.com

 
Cosette Pharmaceuticals is a US based, diversified pharmaceutical company with a proven topicals and dermatology portfolio and a growing branded pharmaceuticals business. We are fully integrated, with a deep focus on internal R&D, high quality manufacturing standards and commercial sales excellence. We continue to diversify and expand through strategic partnerships, acquisitions and internal R&D. Our highly experienced leadership team are busy writing the next, most ambitious chapter of our story. Building on a 100+ year heritage, their shared vision of innovation will leverage the expertise of more than 350+ team members, and infrastructure to create remarkable new opportunities for the ...
  • Number of Employees: 250-1000
  • Annual Revenue: $50-100 Million

Executives

Name Title Contact Details

Similar Companies

Boston Health Care for the Homeless Program

Since its founding in 1985, Boston Health Care for the Homeless Program has been guided by a simple mission - to provide and assure access to the highest quality health care for Bostons homeless men, women and children. http://www.bhchp.org

Avema Pharma Solutions

Avema Pharma Solutions is a Westbury, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

NXT-USA

NXT USA is a company that focuses on developing clinically validated branded ingredients that positively impact global health.

Journey Medical

Journey’s purpose is to positively impact people by providing effective solutions for treating skin conditions, healing wounds, and supporting healthy skin.

Edgewise Therapeutics

Edgewise Therapeutics is a biotechnology company harnessing proven expertise and understanding of skeletal muscle physiology to develop novel, transformative therapies for serious muscle diseases. Based in Boulder, Colorado, we have built a state-of-the-art muscle research facility to capitalize on new insights into the nature and consequences of muscle adaptation and injury with disease. Edgewise recently closed it`s Series B financing round which will support the advancement of Edgewise Therapeutic`s lead product candidate into clinical development for Duchenne and Becker Muscular Dystrophy (DMD and BMD) as well as expansion of the company`s pipeline. The company`s leadership team has founded multiple biotechnology startups, several of which have gone on to become publicly-traded companies and brings to bear a depth of experience in drug discovery, development and commercialization.